7 Questions Every CEO Should Ask Before Launching a Clinical Trial

Most Clinical Trial Delays Are Visible Before the Study Begins

Clinical trial delays are often treated as unexpected operational challenges.

Enrollment falls behind plan. Site performance varies. Retention becomes more difficult than anticipated. Timelines extend. Budgets increase.

From the outside, these issues can appear to be execution problems. In reality, many of the factors that contribute to trial delays are visible long before the first patient enrolls.

That is why clinical trial readiness is not simply an operational responsibility. It is a leadership responsibility.

CEOs may not be involved in day-to-day trial management, but the questions they ask before study launch can have a meaningful impact on recruitment timelines, operational efficiency, and overall study success.

The most successful leaders do not assume their teams have identified every risk. They ask questions designed to uncover what might be missing.

Here are seven of the most important questions every CEO should ask before launching a clinical trial.

1. Do We Truly Understand the Patients We Need to Reach?

Many organizations spend months evaluating investigators, sites, vendors, and protocol requirements. Far fewer spend the same amount of time understanding the patients they ultimately need to recruit.

Yet patients determine whether a trial succeeds or struggles.

Before launch, CEOs should understand whether their teams have evaluated:

• Patient demographics
• Geographic distribution
• Treatment pathways
• Common participation barriers
• Caregiver involvement
• Community dynamics
• Advocacy landscape

Without this understanding, recruitment plans are often built on assumptions instead of insights.

The result can be recruitment strategies that look strong on paper but fail to align with how patients actually make participation decisions.

Understanding the patient landscape is not simply a patient engagement exercise. It is a risk management exercise.

2. Have We Asked Patients to Review Our Assumptions?

Internal teams possess scientific, medical, and operational expertise.

Patients possess lived experience.

Both perspectives are necessary.

Organizations frequently develop protocols, recruitment materials, educational resources, and engagement strategies without directly validating their assumptions with patients.

As a result, challenges that seem invisible to study teams become obvious once recruitment begins.

Patients can provide valuable insight regarding:

• Study burden
• Visit frequency
• Travel expectations
• Communication preferences
• Eligibility perceptions
• Participation concerns

Even modest patient feedback efforts can reveal opportunities to improve study readiness before problems emerge.

One of the most expensive assumptions a company can make is believing it already understands what patients need.

3. Are Our Enrollment Expectations Realistic?

Enrollment projections often look impressive during planning.

Unfortunately, projections and reality do not always align.

When recruitment goals are established, CEOs should understand the assumptions behind those numbers.

Questions worth exploring include:

• How were enrollment projections developed?
• What historical performance data supports them?
• What risks could affect timing?
• How dependent are projections on specific sites or locations?
• What contingency planning exists if targets are missed?

Optimistic planning is not inherently problematic.

Unvalidated planning is.

Organizations that challenge assumptions early are often better positioned to respond when conditions change.

4. What Could Make Participation Difficult for Patients?

Many recruitment challenges stem from barriers that have little to do with awareness.

Patients may know a study exists and still choose not to participate.

Common barriers include:

• Travel requirements
• Time commitments
• Caregiver responsibilities
• Work schedules
• Financial concerns
• Technology limitations
• Complex study procedures

If organizations do not actively look for these barriers before launch, they often discover them after recruitment efforts begin.

At that point, potential mitigation strategies become more difficult and expensive to implement.

Strong clinical trial planning requires understanding not only why patients might participate, but also why they might not.

5. Are We Building Trust Before We Need It?

Trust cannot be activated on demand.

Yet many sponsors begin meaningful patient and advocacy engagement only when enrollment support is required.

Communities often recognize the difference between organizations seeking a long-term relationship and those seeking immediate recruitment assistance.

Trust is particularly important in rare disease and highly specialized patient populations where relationships strongly influence engagement.

Before launch, CEOs should consider:

• Have we engaged relevant advocacy organizations?
• Do patients know who we are?
• Have we established credibility within the community?
• Are we viewed as a trusted partner?

Organizations that begin engagement earlier are often better positioned to recruit effectively later.

Trust is not a recruitment tactic.

It is an asset that supports every stage of clinical development.

6. Are Our Sites Prepared for the Patient Experience?

Site readiness and patient readiness are closely connected.

Even when recruitment campaigns perform well, enrollment may struggle if sites are not equipped to support prospective participants effectively.

Executives should understand whether sites have access to:

• Recruitment resources
• Educational materials
• Referral management processes
• Patient support information
• Frequently asked question resources

They should also understand how quickly sites respond to patient inquiries and how consistently information is being communicated.

Patients often evaluate participation decisions based on their earliest interactions with study personnel.

Those experiences matter.

Strong site support can improve both enrollment performance and participant confidence.

7. What Risks Are We Not Discussing?

Perhaps the most important question is also the simplest.

Every trial has risks.

Some are documented. Others are hidden within assumptions, timelines, projections, and operational plans.

Before launch, CEOs should encourage candid discussion regarding:

• Enrollment risks
• Retention risks
• Site performance concerns
• Patient engagement gaps
• Resource constraints
• Operational dependencies

The goal is not to eliminate uncertainty.

The goal is to identify risks while there is still time to address them.

Organizations that create space for honest conversations about vulnerabilities are often better prepared to navigate challenges when they arise.

Strong Clinical Trial Launches Begin with Better Questions

Successful clinical trials are rarely the result of flawless execution alone.

They are usually supported by thoughtful planning, realistic expectations, strong patient understanding, and leadership teams that ask difficult questions early.

Many enrollment, retention, and operational challenges emerge months before they become visible through study metrics.

CEOs who challenge assumptions, encourage patient-centered thinking, and prioritize readiness often create stronger foundations for study success.

The most important contribution a leader can make before launch is not having all the answers.

It is ensuring the organization is asking the right questions.

Better Decisions Start Before First Patient In

Many clinical trial challenges can be identified long before they affect timelines, budgets, or enrollment performance.

PAS helps sponsors evaluate patient readiness, advocacy engagement opportunities, recruitment risks, and study planning assumptions before recruitment begins.

Organizations that understand patients, engage communities early, and proactively address barriers are often better positioned to launch successful studies and achieve enrollment goals.